• 1
    Anonymous 2003 Cancer Facts & Figures 2003. American Cancer Society, Atlanta, GA, USA, p. 4.
  • 2
    Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR 2003 Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:2133.
  • 3
    Mariette X, Khalifa P, Ravaud P, Frija J, Laval-Jeantet M, Chastang C, Brouet JC, Fermand JP 1992 Bone densitometry in patients with multiple myeloma. Am J Med 93:595598.
  • 4
    Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, Kwan YK 1997 Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: Effects of glucocorticoid therapy and disease activity. Br J Haematol 97:641648.
  • 5
    Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC, Barlogie B 1998 Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma 32:121127.
  • 6
    Ingeberg S, Deding A, Jensen MK 1982 Bone mineral content in myelomatosis. Acta Med Scand 211:1921.
  • 7
    Abildgaard N, Brixen K, Kristensen JE, Vejlgaard T, Charles P, Nielsen JL 1996 Assessment of bone involvement in patients with multiple myeloma using bone densitometry. Eur J Haematol 57:370376.
  • 8
    Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C 1991 Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88:6266.
  • 9
    Bataille R, Chappard D, Basle M-F 1996 Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies. Blood 87:47624769.
  • 10
    Bataille R 1997 New insights in the clinical biology of multiple myeloma. Semin Hematol 34(Suppl 1):2328.
  • 11
    Berenson JR 2002 Advances in the biology and treatment of myeloma bone disease. Semin Oncol 29(Suppl 17):1116.
  • 12
    Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, Sagaster P, Köhn H, Bayer P, Thiébaud D, Ludwig H 1997 Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by urinary pyridinium cross-linkage of collagen. Blood 90:37433750.
  • 13
    Vejlgaard T, Abildgaard N, Jans H, Nielsen JL, Heickendorff L 1997 Abnormal bone turnover in monoclonal gammopathy of undetermined significance: Analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Eur J Haematol 58:104108.
  • 14
    Diamond T, Levy S, Smith A, Day P, Manoharan A 2001 Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Int Med J 31:272278.
  • 15
    Williams AT, Shearer MJ, Oyeyi J, Aitchison RG, Newland AC, Schey SA 1992 Serum osteocalcin in the management of myeloma. Eur J Cancer 29A:140142.
  • 16
    Laroche M, Attal M, Dromer C 1996 Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma. Clin Rheumatol 15:347352.
  • 17
    Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ III 2002 A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564569.
  • 18
    Bergsagel D 1995 The incidence and epidemiology of plasma cell neoplasms. Stem Cells 13(Suppl 2):19.
  • 19
    Kyle RA 2000 The role of bisphosphonates in multiple myeloma. Ann Intern Med 132:734736.
  • 20
    Berenson JR 2001 Bone disease in myeloma. Curr Treatment Options Oncol 2:271283.
  • 21
    Melton LJ III 1996 History of the Rochester Epidemiology Project. Mayo Clin Proc 71:266274.
  • 22
    Melton LJ III 1997 The threat to medical-records research. N Engl J Med 337:14661470.
  • 23
    Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III 1992 Incidence of clinically diagnosed vertebral fractures: A population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 7:221227.
  • 24
    Melton LJ III, Sampson JM, Morrey BF, Ilstrup DM 1981 Epidemiologic features of pelvic fractures. Clin Orthop 155:4347.
  • 25
    Rose SH, Melton LJ III, Morrey BF, Ilstrup DM, Riggs BL 1982 Epidemiologic features of humeral fractures. Clin Orthop 168:2430.
  • 26
    Melton LJ III, Atkinson EJ, Madhok R 1996 Downturn in hip fracture incidence. Public Health Rep 111:146150.
  • 27
    Melton LJ III, Amadio PC, Crowson CS, O'Fallon WM 1998 Long-term trends in the incidence of distal forearm fractures. Osteoporos Int 8:341348.
  • 28
    Melton LJ III, Crowson CS, O'Fallon WM 1999 Fracture incidence in Olmsted County, Minnesota: Comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:2937.
  • 29
    Cox DR 1953 Some simple approximate tests for Poisson variates. Biometrika 40:354360.
  • 30
    Kaplan EL, Meier P 1958 Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457481.
  • 31
    Kalbfleisch JD, Prentice RL 1980 The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York, NY, USA.
  • 32
    Cox DR 1972 Regression models and life-tables (with discussion). J R Stat Soc 34:187220.
  • 33
    Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS 2002 American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20:37193736.
  • 34
    Laroche M, Pouillès JM, Dromer C, Attal M, Ribot C 1996 Dual-energy x-ray absorptiometry in patients with multiple myeloma and benign gammopathies. Clin Exp Rheumatol 14:108.
  • 35
    Riggs BL, Melton LJ 2002 Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:1114.
  • 36
    Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M 2001 Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 47:686693.
  • 37
    Holmes JA, Evans WD, Cole RJ, Ramsahoye B, Whittaker JA 1994 Letter to the editor: Dual energy X-ray absorptiometry measurements of bone mineral density in myeloma. Eur J Haematol 53:309311.
  • 38
    Bataille R, Chappard D, Marcelli C, Rossi J-F, Dessauw P, Baldet P, Sany J, Alexandre C 1990 Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 76:484487.
  • 39
    Melton LJ III, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL 1993 Prevalence and incidence of vertebral deformities. Osteoporos Int 3:113119.
  • 40
    Cummings SR, Melton LJ 2002 Epidemiology and outcomes of osteoporotic fractures. Lancet 359:17611767.
  • 41
    Cauley JA, Salamone LM 2001 Postmenopausal endogenous and exogenous hormones, degree of obesity, thiazide diuretics and risk of osteoporosis. In: MarcusR, FeldmanD, KelseyJ (eds.) Osteoporosis, 2nd ed., vol. 1. Academic Press, San Diego, CA, USA, pp. 741769.
  • 42
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M 2000 Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 15:721739.
  • 43
    Tannirandorn P, Epstein S 2000 Drug-induced bone loss. Osteoporos Int 11:637659.